BACKGROUND: For ambulatory cancer patients, Ontario has standardized symptom and performance status assessment population-wide, using the Edmonton Symptom Assessment System (ESAS) and Palliative Performance Scale (PPS). In a broad cross-section of cancer outpatients, the authors describe the ESAS and PPS scores and their relation to patient characteristics. METHODS: This is a descriptive study using administrative healthcare data. RESULTS: The cohort included 45,118 and 23,802 patients' first ESAS and PPS, respectively. Fatigue was most prevalent (75%), and nausea least prevalent (25%) in the cohort. More than half of patients reported pain or shortness of breath; about half of those reported moderate to severe scores. Seventy-eight percent had stable performance status scores. On multivariate analysis, worse ESAS outcomes were consistently seen for women, those with comorbidity, and those with shorter survivals from assessment. Lung cancer patients had the worst burden of symptoms. CONCLUSIONS: This is the first study to report ESAS and PPS scores in a large, geographically based cohort with a full scope of cancer diagnoses, including patients seen earlier in the cancer trajectory (ie, treated for cure). In this ambulatory cancer population, the high prevalence of numerous symptoms parallels those reported in palliative populations and represents a target for improved clinical care. Differences in outcomes for subgroups require further investigation. This research sets the groundwork for future research on patient and provider outcomes using linked administrative healthcare data.
BACKGROUND: For ambulatory cancerpatients, Ontario has standardized symptom and performance status assessment population-wide, using the Edmonton Symptom Assessment System (ESAS) and Palliative Performance Scale (PPS). In a broad cross-section of cancer outpatients, the authors describe the ESAS and PPS scores and their relation to patient characteristics. METHODS: This is a descriptive study using administrative healthcare data. RESULTS: The cohort included 45,118 and 23,802 patients' first ESAS and PPS, respectively. Fatigue was most prevalent (75%), and nausea least prevalent (25%) in the cohort. More than half of patients reported pain or shortness of breath; about half of those reported moderate to severe scores. Seventy-eight percent had stable performance status scores. On multivariate analysis, worse ESAS outcomes were consistently seen for women, those with comorbidity, and those with shorter survivals from assessment. Lung cancerpatients had the worst burden of symptoms. CONCLUSIONS: This is the first study to report ESAS and PPS scores in a large, geographically based cohort with a full scope of cancer diagnoses, including patients seen earlier in the cancer trajectory (ie, treated for cure). In this ambulatory cancer population, the high prevalence of numerous symptoms parallels those reported in palliative populations and represents a target for improved clinical care. Differences in outcomes for subgroups require further investigation. This research sets the groundwork for future research on patient and provider outcomes using linked administrative healthcare data.
Authors: Amanda Digel Vandyk; Margaret B Harrison; Gail Macartney; Amanda Ross-White; Dawn Stacey Journal: Support Care Cancer Date: 2012-04-17 Impact factor: 3.603
Authors: L Barbera; H Seow; R Sutradhar; A Chu; F Burge; K Fassbender; K McGrail; B Lawson; Y Liu; R Pataky; A Potapov Journal: Curr Oncol Date: 2015-10 Impact factor: 3.677
Authors: Dawn Stacey; Esther Green; Barbara Ballantyne; Myriam Skrutkowski; Angela Whynot; Lucie Tardif; Joy Tarasuk; Meg Carley Journal: Support Care Cancer Date: 2015-08-15 Impact factor: 3.603
Authors: Adam E Singer; Daniella Meeker; Joan M Teno; Joanne Lynn; June R Lunney; Karl A Lorenz Journal: Ann Intern Med Date: 2015-02-03 Impact factor: 25.391
Authors: Andrea L Cheville; Jeffrey R Basford; Ian Parney; Ping Yang; Felix E Diehn Journal: Arch Phys Med Rehabil Date: 2016-09-22 Impact factor: 3.966
Authors: Adam E Singer; Daniella Meeker; Joan M Teno; Joanne Lynn; June R Lunney; Karl A Lorenz Journal: J Palliat Med Date: 2016-07-25 Impact factor: 2.947